BioPharmSignal logoBioPharmSignal

Biotech News

Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Ascendis Pharma (ASND)Ascendis PharmaConference / presentation

COPENHAGEN, Denmark, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time / 5:30 a.m.

Related news

ASNDAscendis Pharma2026-03-02 13:43 EST

Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference

ASNDAscendis Pharma2026-06-26 20:01 EST

Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®

View all latest news

Ascendis Pharma

TransCon Technology Ascendis Pharma applies its TransCon prodrug platform to create long-acting therapies that release an unmodified parent drug over time. Its portfolio spans endocrinology, rare growth disorders and oncology. Commercial Endocrinology Portfolio YORVIPATH is a parathyroid-hormone replacement therapy for chronic...

Recent company news

ASNDAscendis Pharma2026-09-14 22:00 EST

Ascendis Announces Planned $400 Million Share Repurchase Program

ASNDAscendis Pharma2026-09-14 22:00 EST

Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases

ASNDAscendis Pharma2026-09-09 20:01 EST

First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026

ASNDAscendis Pharma2026-09-08 20:01 EST

Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

ASNDAscendis Pharma2026-09-07 11:00 EST

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026

Stock data

Close
239.04 USD
Market cap
13.38B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States